Related Experiment Video
Updated: May 31, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Synthetic data as external control arms in scarce single-arm clinical trials
Severin Elvatun1, Daan Knoors1, Simon Brant2
1Cancer Registry of Norway, Norwegian Institute of Public health, Ullernchausseen 64, 0379 Oslo, Norway.
Abstract:
An external control arm based on health registry data can serve as an alternative comparator in single-arm drug development studies that lack a benchmark for comparison to the experimental treatment. However, accessing such observational healthcare data involves a lengthy and intricate application process, delaying drug approval studies and access to novel treatments. Clinical trials typically comprise only a few hundred patients usually with high-cardinality features, which makes individual data instances more exposed to re-identification attacks. We examine whether synthetic data can serve as a proxy for the empirical control arm data by providing the same research outcomes while reducing the risk of information disclosure. We propose a reversible data generalization procedure to address these particular data characteristics that can be used in conjunction with any generator algorithm. It reduces the input data cardinality pre-synthesis and reverses it post-synthesis to regain the original data structure. Finally, we test a selection of state-of-the-art generators against a suite of utility and privacy metrics. The external control arm benchmark was generated using data from Norwegian health registries. In this retrospective study, we compare various synthetic data generation algorithms in numerical experiments, focusing on the utility of the synthetic data to support the conclusions drawn from the empirical data, and analysing the risk of sensitive information disclosure. Our results indicate that data generalization is advantageous to enhance both data utility and privacy in smaller datasets with high cardinality. Moreover, the generator algorithms demonstrate the ability to generate synthetic data of high utility without compromising the confidentiality of the empirical data. Our finding suggests that synthetic external control arms could serve as a viable alternative to observational data in drug development studies, while reducing the risk of revealing sensitive patient information.
Insights
Synthetic data can replace health registry data for external control arms in drug development. This approach maintains research outcomes while enhancing patient privacy and accelerating studies.
Area of Science:
- Health Informatics
- Data Science
- Pharmacology
Background:
- Single-arm drug development studies often lack comparators.
- Health registry data offers an alternative but has access barriers.
- Clinical trial data is vulnerable to re-identification due to small sample sizes and high-cardinality features.
Purpose of the Study:
- To evaluate synthetic data as a privacy-preserving proxy for empirical external control arm data.
- To assess the utility and privacy risks of synthetic data in drug development.
- To introduce a reversible data generalization procedure for enhancing synthetic data generation.
Main Methods:
- A reversible data generalization procedure was proposed and applied.
- State-of-the-art synthetic data generators were tested.
- Synthetic data utility and privacy metrics were evaluated using Norwegian health registry data.
Main Results:
- Data generalization improved both utility and privacy for small, high-cardinality datasets.
- Generators produced high-utility synthetic data without compromising empirical data confidentiality.
- Synthetic external control arms demonstrated viability as an alternative to observational data.
Conclusions:
- Synthetic data, particularly with data generalization, can effectively serve as external control arms in drug development.
- This method enhances patient privacy and potentially accelerates drug approval processes.
- Synthetic data offers a secure and efficient alternative for comparative studies in pharmaceutical research.
More Related Videos
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Hazard Ratio
For example, in a clinical trial...